Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

MedGenome Strengthens Leadership Team to Drive North American Expansion in Precision Medicine

NCCN Expands Clinical Practice Guidelines for High-Risk Genetic Cancer Assessment

Home
/
update
/
details

Pfizer Promotes BRAF Mutation Testing in Lung Cancer to Expand Braftovi Market

NextEdge Admin

17 Sep 2024

2 min 15 sec

Pfizer is working to increase awareness among doctors about testing for a rare lung cancer mutation, aiming to boost the use of its drug Braftovi, which it hopes will become the standard of care. At a recent conference, the company presented three-year data from a Phase 2 study on patients with BRAF V600E-mutant metastatic non-small cell lung cancer. Those treated with Braftovi, in combination with another Pfizer drug, Mektovi, had a median progression-free survival of over two-and-a-half years. This suggests the treatment can significantly delay the worsening of cancer.

Chris Boshoff, Pfizer's Chief Oncology Officer, stated that the data supports Braftovi as a standard treatment for this patient group. Approximately 2% to 3% of lung cancer patients have the BRAF mutation. Currently, the standard of care includes immunotherapy and chemotherapy, but fewer than 50% of U.S. lung cancer patients are tested for the mutation, with even lower rates globally. Boshoff emphasized that testing for BRAF mutations could be done through a simple blood test, covered by insurance in the U.S.

Pfizer sold nearly $400 million worth of Braftovi and Mektovi last year. The company also sees potential growth in colorectal cancer, where BRAF mutations are present in 10% of cases, with data from a late-stage study expected by year-end. Pfizer is focusing on global efforts to encourage testing and educate healthcare professionals, patients, and advocacy groups.